TANG Jia ping,JIANG Yan ling,CHANG Jing,et al.Efficacy and safety of propranolol for Hemangioma in 225 chicdren.[J].Journal of Clinical Pediatric Surgery,,10():0.
Efficacy and safety of propranolol for Hemangioma in 225 chicdren.
- Abstract:
- ObjectiveTo evaluate the efficacy and safety of propanolol in the treatment of infantile hemangiomas.MethodsA total of 225 patients aged 20 days to 16 years underwent propanolol treatment for problematic proliferating haemangioma, 74 boys and 151 girls. 199 patients had a solitary haemangioma, 18 had multiple haemangiomas (2-5 area), 2 had hemangiomathrombocytopenia syndrome and 6 had infants generalized hemangioma (3 had hepatic hemangioma). 15 cases of vascular malformation patients as the control group. All the patients were initially managed as inpatients and received tumor, abdominal and heart color ultrasound scan, ultrasound scan, ECG, head MRI, blood glucose, thyroid function, liver function and nephric function examination before taking propanolol. Then they were treated with propanolol at 1.5-2mg/kg/day in 2 divided doses. All the patients received general electrocardiogram monitoring in the first three days. They were discharged with oral propanolol if no cardiovascular or metabolic side effect were observed after 3 or 4 days. The patients were revisited once a month and the therapeutic effects were evaluated using a 4-point scale system. All patients were followed up in December 2010.Results213 patients insisted on the treatment for more than 1 months，among them, 19 was scale Ⅰ (poor), 52 was scale Ⅱ (moderate), 60 was scale Ⅲ (good) and 82 scale Ⅳ (excellent). The efficacy rate was 91.08% and 17 of the patients recovered completely. Its efficacy was significantly higher than the group of vascular malformation (P<0001). The efficacy was increased with prolonged treatment. No significant adverse reactions was observed and the overall adverse event incidence rate was 2.08%.ConclusionPropanolol is safe and effective in the treatment of hemangiomas, no serious side effects was observed and should be first line therapeutic strategy for hemangioma
References:
1Mulliken JB,Young AE.Vascular Birthmarks: Hemangiomas and Vascular Malformations\[M\].Philadelphia: Saunders，1988.30—231.
2中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组\[D\].中华口腔医学杂志,2005，40（3）：185—186.
3LeauteLabreze C,Dumas de la Roque E,Hubiche T,et al. Propranolol for severe hemangiomas of infancy\[J\].N Engl J Med,2008, 358 (24): 2649—2651.
4Storch CH，Hoeger PH. Propranolol for infantile haemangiomasinsights into the molecular mechanisms of action\[J\].Br J Dermatol,2010,163(2):269—274.
5Cheng JF,Gole GA,Sullivan TJ.Propranolol in the management of periorbital infantile haemangioma\[J\].Clin Experiment Ophthalmol,2010,38(6):547—553.
6Arneja JS,Pappas PN,Shwayder TA,et al.Management of complicated facial hemangiomas with betablocker (propranolol) therapy\[J\].Plast Reconstr Surg, 2010,126(3):889—895.
Memo
作者单位：湖南省儿童医院皮肤科（长沙市，410007）,本研究为湖南省科技厅科研立项课题(项目号2010FJ6001)·